glp 1 gene GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Full-length human GLP-1 receptor structure
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 5.Luo J., Feldman R., Kim K.C., et al
![glp 1 gene GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Full-length human GLP-1 receptor structure](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-020-14934-5/MediaObjects/41467_2020_14934_Fig1_HTML.png)
If you start Yerba mate, watch your blood pressure closely, monitoring daily for 2 weeks before and 2 weeks after starting to judge if the supplement is causing blood pressure to rise
![glp 1 gene GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Full-length human GLP-1 receptor structure](https://www.researchgate.net/publication/387190167/figure/fig1/AS:11431281306552375@1738298923410/Glucagon-like-peptide-1-GLP-1-and-its-functional-mechanisms-associated-with-weight.png)
The gap between marketing claims and published evidence is where supplements either earn credibility or lose it entirely
![glp 1 gene GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Full-length human GLP-1 receptor structure](https://www.bocsci.com/upload/image/mechanism-of-action-of-glp-1-binding-to-glp-1r.jpg)
Bohn, M
![glp 1 gene GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Full-length human GLP-1 receptor structure](https://pancreapedia.org/sites/default/files/Figure%201_Williams.jpg)
Providing access to proven GLP-1 medications could benefit health outcomes for a wide group of Americans and reduce the strain on the healthcare system associated with treating diabetes and related conditions
![glp 1 gene GLP-1 Agonists Can Be Heaven or Hell Dependent Upon Dopaminergic Genetic/Epigenetic Antecedents[v1] Full-length human GLP-1 receptor structure](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs43856-025-00959-8/MediaObjects/43856_2025_959_Fig1_HTML.png)
Future investigations should incorporate models of fibrous-cap thinning, plaque instability, and rupture-prone lesions to determine whether GLP-1RAs protect the full spectrum of atherosclerotic progression